95058-81-4 | Gemcitabine

Chemical type

• Nucleoside analog
• Antimetabolite

^[1]

• Cytidine analog
• Pyrimidine nucleoside derivative

^[2]

Key properties

• Chemotherapeutic agent
• Interferes with DNA synthesis

^[1]

• High affinity for bacterial transporters (KM 2.5–3.0 µM for NupG orthologs; KM 10–13 µM for NupC orthologs)
• 15–100 times higher affinity than human transporter hENT1/SLC29A1
• Metabolized by gamma-proteobacteria (via cytidine deaminase) to less active deaminated form (2',2'-difluoro-2'-deoxyuridine)
• Incorporated into DNA/RNA, inhibiting nucleotide metabolism and causing cytotoxicity
• Competitively inhibited by natural nucleosides like cytidine and uridine

^[2]

• Chemotherapy drug for high-risk liver hepatocellular carcinoma (HCC) patients
• Shown to have greater sensitivity in treating high-risk HCC patients

^[1]

• Anticancer drug for pancreatic ductal adenocarcinoma and other aggressive cancers
• Frontline chemotherapy agent
• Transported and metabolized by tumor-associated bacteria, contributing to chemoresistance

^[2]

Classification by use

• Chemotherapy drugs

^[1]

• Chemotherapy agents
• Substances involved in bacteria-mediated drug resistance

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Anoikis- and m6A-related lncRNA analysis to identify prognostic indicators in liver hepatocellular carcinoma, Electronic Journal of Biotechnology, Volume 79, January 2026, 100701
2. [Cite:2] Elucidation of the Gemcitabine Transporters of Escherichia coli K-12 and Gamma-Proteobacteria Linked to Gemcitabine-Related Chemoresistance, Int. J. Mol. Sci., 2024, 25(13), 7012